Thomas

Ferdinand Los, CSO at Hudson River Biotechnology: “We strongly believe in our ability to keep innovating and be at the forefront of technological developments. This funding is another building block, which will allow us to further scale up the existing gene editing business.” Additionally, HRB will grow its staff count from 25 to 40 in …

Hudson River Biotechnology raises €5m Series A funding to accelerate growth of its plant gene editing business and expand into nanoparticles for use in field applications Lees verder »

In an opinion piece on AgFunder, our founders Rudi Ariaans and Ferdinand Los argue that CRISPR is the best tool the EU has to achieve its ambitious agrifood sustainability goals. The bloc needs to keep that squarely in mind when regulating its use. Read the article here.

Bionieuws, the Dutch magazine for biologists interviewed our CSO Ferdinand Los, and published a short company profile in their magazine. Read the article here.

Prof. John van der Oost, head of the Bacterial Genetics group in the Laboratory of Microbiology at Wageningen University, has joined the Scientific Advisory Board of Hudson River Biotechnology (HRB). Prof. van der Oost is considered a pioneer of the “CRISPR revolution” for his fundamental work on unravelling the mechanism of CRISPR-based immunity in bacteria, …

Prof. John van der Oost joins Hudson River Biotechnology’s Advisory Board Lees verder »